Explore every episode of the podcast JNM Podcast

Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment.  Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, MD, and Irene Buvat, PhD. The panel also discusses the role of AI tools in analyzing risk and response assessment in lymphoma. Tune in now!

Below are resources provided by Dr. Barrington: 

Tool to measure the international metabolic prognostic index 'IMPI':https://petralymphoma.org/impi/

Benchmark dataset for MTV measurement:   https://zenodo.org/records/11409717

For more JNM articles on this topic, see below:

Methodology for MTV described in DOI: https://jnm.snmjournals.org/content/early/2020/07/16/jnumed.119.238923

Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening? https://doi.org/10.2967/jnumed.123.267022

Deep learning enables TMTV estimation  https://doi.org/10.2967/jnumed.120.242412

This episode is sponsored by SOFIE Biosciences:

Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patient and treatment data. Plus, what's next for PSMA as it matures into adulthood? Tune in to find out!

Thanks to Sofie Biosciences for sponsoring this episode. https://sofie.com/

The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, which may make cardiac imaging more accessible to patients across the country. Here to discuss the utility of the F-18 label and the future of myocardial perfusion imaging are Jamshid Maddahi, MD, FACC, FASNC, and Sharmila Dorbala, MD, MPH.

Thanks to GE Healthcare for sponsoring this episode! https://www.gehealthcare.com/products/molecular-imaging-agents/flyrcado

Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune in now!

Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/

Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients.

Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/

Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.

Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). 
Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis, Basel, Switzerland), and Désirée Deandreis, MD (Gustave Roussy, Villejuif, France).

Sponsored by SOFIE Biosciences (https://sofie.com) 

The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine.

Moderators: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany) and Heiko Schoder, MD, MBA (Memorial Sloan Kettering Cancer Center)

Panelist: Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center)

Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/

This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD, leads this intercontinental panel in a discussion about other radionuclides and their pros and cons. He's joined by David Bauer, PhD, from Memorial Sloan Kettering Cancer Center, Jane Sosabowski, BSc, MSc, PhD, from Queen Mary, University of London, and Nick Fletcher, PhD, from the University of Queensland, Australia.

The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches.
Panel: 
• Ken Herrmann, MD, MBA (Universitätsmedizin, Essen, Germany)
• Henryk Barthel, MD, PhD (Leipzig University)
• Gil Rabinovici, MD (University of California - San Francisco)
• Victor Villemagne, MD (University of Pittsburgh)

The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss challenges, and predict the pathway to clinical success. #JNuclMed #NuclearMedicine #FAPI #Theranostics